Compare GSK plc (GSK) vs Advanced Drainage Systems Inc (WMS) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

WMS trades at $152.70, up 1.1% on the day, with a bullish technical signal and strong profitability metrics including a 13.98% net income margin and 24.02% ROE. The company recently beat Q1 2026 EPS estimates and announced a dividend, while cash flow from operations remains healthy at $581.49M for 2025. Revenue has been stable around $2.9B, though net income dipped to $450.17M in 2025 from prior years.

Outlook is mixed: analyst consensus targets $184.43 (21% upside) with 41% buy ratings, but a Zacks Strong Sell rating and projected 2026 earnings decline pose risks. Investment appeal lies in valuation support and operational strength, countered by earnings volatility and competitive pressures in water management solutions.